Report from the First Clinical Trials on Alzheimer's Disease (CTAD) Asia-China 2018 : Bringing together Global Leaders.
Alzheimer’s disease
CTAD
China
Dementia
chinese
clinical trials
Journal
The journal of prevention of Alzheimer's disease
ISSN: 2426-0266
Titre abrégé: J Prev Alzheimers Dis
Pays: Switzerland
ID NLM: 101638820
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
24
7
2020
Statut:
ppublish
Résumé
Population of older adults in Asia, and particularly in China is increasing rapidly. Older population are at increased risk of Alzheimer's disease (AD) and other dementias. Soon, the Chinese population with AD will represent almost half of the world's AD population. There is a desperate need of disease modifying therapies to delay or slow the progression of AD, to tackle this emerging healthcare emergency. In this context, the first CTAD Asia-China conference was held in China to bring together Western and Asian leaders in AD. This meeting focused largely on how to develop successful trials in China, utilizing past experiences from the West.
Identifiants
pubmed: 30756122
doi: 10.14283/jpad.2019.2
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
144-147Déclaration de conflit d'intérêts
None